Community/Retail

The FDA has expanded the indication of the antiepileptic drug perampanel (FYCOMPA®, Eisai) CIII for monotherapy and adjunctive use in pediatric patients aged 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.